Hepatitis C in cirrhosis patients: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Hepatitis C}} {{CMG}}; {{AOEIC}} {{VK}} ==Recommendations for Treatment of Persons with Compensated and Decompensated Cirrhosis: AASLD Practice Guidelines 2009<ref name="pm...")
(No difference)

Revision as of 22:35, 23 February 2012

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C in cirrhosis patients On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C in cirrhosis patients

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C in cirrhosis patients

CDC on Hepatitis C in cirrhosis patients

Hepatitis C in cirrhosis patients in the news

Blogs on Hepatitis C in cirrhosis patients

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C in cirrhosis patients

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Recommendations for Treatment of Persons with Compensated and Decompensated Cirrhosis: AASLD Practice Guidelines 2009[1]

1.Patients with HCV-related compensated cirrhosis (CTP class A), can be treated with the standard regimen of pegylated interferon and ribavirin but will require close monitoring for adverse events (Class I, Level A).

2. Patients with HCV-related decompensated cirrhosis should be referred for consideration of liver transplantation (Class I, Level B).

3. Interferon-based therapy may be initiated at a lower dose in patients with decompensated cirrhosis (CTP class B and C), as long as treatment is administered by experienced clinicians with vigilant monitoring for adverse events preferably in patients who have already been accepted as candidates for liver transplantation (Class IIb, Level B).

4. Growth factors can be used for treatment-associated anemia and leukopenia to improve quality of life and may limit the need for antiviral dose reductions in patients with decompensated cirrhosis (Class IIb, Level C).

References

  1. Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter |month= ignored (help)

Template:WS Template:WH